We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Amgen Scoffs At Roche Proposal In EPO Patent Battle

Law360 (February 21, 2008, 12:00 AM EST) -- Amgen Inc. reiterated its desire for a permanent injunction barring F. Hoffman-La Roche Ltd.'s anemia treatment Mircera from the U.S. market, in response to the Swiss company's proposal to make the peg-EPO product available to patients in America and pay Amgen a 20% royalty on Mircera's U.S. sales.

Amgen filed a brief on Tuesday comparing Roche to a “snake-oil salesman” and arguing that U.S. District Judge William G. Young should issue an injunction barring Roche from selling any peg-EPO product in the U.S. for the term...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.